The 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (PH) are developed by a task force comprising experts from the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). The guidelines are endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). They provide comprehensive clinical practice recommendations for managing PH, with a focus on pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH). Key updates include: - Reconsideration of the hemodynamic definition of PH, including revised cut-off levels for pulmonary vascular resistance (PVR) and exercise PH. - Updated classification of PH, including repositioning of vasoreactive patients with idiopathic PAH and revisions to Group 5 PH. - Development of a new algorithm for earlier detection of PH in the community, with expedited referral for high-risk or complex patients. - Expansion of the risk-stratification table to include additional echocardiographic and cardiac magnetic resonance imaging (cMRI) prognostic indicators. - Simplification of initial drug therapy recommendations based on a revised, three-strata, multiparametric risk model. - Introduction of a four-strata risk-assessment tool for follow-up, categorizing patients as low, intermediate-low, intermediate-high, or high risk. - Modified PAH treatment algorithm emphasizing cardiopulmonary comorbidities, risk assessment, and combination therapies. - Updated recommendations for managing PH associated with left heart disease (PH-LHD) and lung disease. - Introduction of the term "chronic thrombo-embolic pulmonary disease (CTEPD) with or without PH" and upgraded interventional treatment options for CTEPH. - New standards for PH centers and active involvement of patient representatives in guideline development. The guidelines aim to streamline PH care, improve diagnostic accuracy, and enhance treatment outcomes through a multidisciplinary approach. They are intended for use by health professionals to guide clinical decision-making, but final decisions should be made in consultation with patients and caregivers.The 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (PH) are developed by a task force comprising experts from the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). The guidelines are endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). They provide comprehensive clinical practice recommendations for managing PH, with a focus on pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH). Key updates include: - Reconsideration of the hemodynamic definition of PH, including revised cut-off levels for pulmonary vascular resistance (PVR) and exercise PH. - Updated classification of PH, including repositioning of vasoreactive patients with idiopathic PAH and revisions to Group 5 PH. - Development of a new algorithm for earlier detection of PH in the community, with expedited referral for high-risk or complex patients. - Expansion of the risk-stratification table to include additional echocardiographic and cardiac magnetic resonance imaging (cMRI) prognostic indicators. - Simplification of initial drug therapy recommendations based on a revised, three-strata, multiparametric risk model. - Introduction of a four-strata risk-assessment tool for follow-up, categorizing patients as low, intermediate-low, intermediate-high, or high risk. - Modified PAH treatment algorithm emphasizing cardiopulmonary comorbidities, risk assessment, and combination therapies. - Updated recommendations for managing PH associated with left heart disease (PH-LHD) and lung disease. - Introduction of the term "chronic thrombo-embolic pulmonary disease (CTEPD) with or without PH" and upgraded interventional treatment options for CTEPH. - New standards for PH centers and active involvement of patient representatives in guideline development. The guidelines aim to streamline PH care, improve diagnostic accuracy, and enhance treatment outcomes through a multidisciplinary approach. They are intended for use by health professionals to guide clinical decision-making, but final decisions should be made in consultation with patients and caregivers.